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Background: Exposure to paraquat results in acute lung injury. A systemic inflammatory response has been widely
established as a contributor to paraquat-induced acute lung injury. Recent studies have reported that consumption
of Xuebijing prevents inflammatory response-induced diseases. This study investigated whether consumption of
Xuebijing protected rats against paraquat-induced acute lung injury.
Methods: Adult male Sprague Dawley rats were randomly divided into four groups: control group; paraquat group;
paraquat + Xuebijing group; and paraquat + dexamethasone group. Rats in the paraquat, paraquat + Xuebijing and
paraquat + dexamethasone groups were intraperitoneally injected with paraquat (30 mg/kg) or administered
paraquat and Xuebijing at 8 mL/kg or dexamethasone at 5 mg/kg, respectively, via an injection into the tail vein.
Lung p38 MAPK, NF-κB65, IkB, p-IκB-α, HIF-1α, Nrf2 and TGF-β1 expression were essayed using western blotting.
IL-6, TNF-α, IL-1β, IL-10, TGF-β1 and PIIIP were measured using ELISA. ROS, oxidised glutathione and glutathione
activity were measured.
Results: After inducing acute lung injury with paraquat for 24 h, Xuebijing was observed to block lung p-p38 MAPK,
NF-κB65, HIF-1α, p-IκB-α and TGF-β1 expression, and increased Nrf2 and IkB expression. The numbers of neutrophils
and lymphocytes and total number of cells were significantly lower in the Xuebijing group compared with the
control group. IL-6, TNF-α, IL-1β, TGF-β1 and PIIIP levels were significantly decreased in the Xuebijing group. ROS
and oxidised glutathione activity were markedly inhibited by Xuebijing. Histological evaluation showed attenuation
of the effects of Xuebijing on paraquat-induced lung injury. Compared with the paraquat + dexamethasone group,
the Xuebijing + paraquat group showed no significant differences.
Conclusions: Inhibiting the expression of p38 MAPK and NF-κB65 was crucial for the protective effects of Xuebijing on
paraquat-induced acute lung injury. The findings suggest that Xuebijing could effectively ameliorate paraquat-induced
acute lung injury in rats. Xuebijing was as effective as dexamethasone at improving paraquat-induced lung injury by
regulating lung inflammation, lung function and oxidative stress responses.
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Paraquat (1,1-dimethyl-4,4-bipyridilium dichloride) is a
widely used contact and nonselective quaternary nitrogen
herbicide. Since its first introduction into agricultural use in
1962, it has caused thousands of human deaths, either by
accidental or voluntary ingestion. The toxicity of paraquat
is based on its induction of redox cycling, which results in
oxidative stress-related cell death and inflammation. Be-
cause of its selective accumulation in the lungs, it causes
severe lung injury, manifesting in oedema, haemorrhage,
interstitial inflammation, and progressive fibrosis [1,2].
Many studies have suggested that the mechanisms of
paraquat-induced lung injury are mainly associated with
the systemic inflammatory response [3,4]. Histologically,
acute lung injury (ALI) in humans is characterised by a
severe acute inflammatory response in the lungs and neu-
trophilic alveolitis [5]. The physiological hallmark of acute
respiratory distress syndrome is disruption of the alveolar-
capillary membrane barrier, which results in the develop-
ment of noncardiogenic pulmonary oedema in which a
proteinaceous exudate floods the alveolar spaces, impairs
gas exchange and precipitates respiratory failure [6,7]. ALI
can result in persistent respiratory failure and prolonged
dependence on mechanical ventilation, thereby increasing
susceptibility to multiorgan dysfunction and mortality [8].
Despite extensive investigation aimed at early diagnostic
and pathogenic factors of ALI, current management is
mainly supportive because specific therapies have not
been identified [9-11]. Animal models focused on ALI pa-
thogenesis have yielded insights into mechanisms that ini-
tiate injury; however, little is known about the potential
determinants of treatment [12,13]. Thus, new strategies
are still required to achieve effective treatment of ALI,
which might ultimately aid in clinical therapy for ALI
patients.
Numerous basic and clinical studies have demonstrated
that overexpression of TNF-α and IL-1ß can induce ALI
[14]. In addition, cytokine production is associated with
activation of the p38-mitogen activated protein kinase
(p38 MAPK) pathway [15]. Cytokine production is also
regulated by p38 MAPK. Inactivated p38 MAPK is nor-
mally located in the cytoplasm and is translocated into nu-
clei following activation, where it activates the activator
protein-1 by phosphorylating myocyte-specific enhancer
factor-2C, activating transcription factor-2, and E twenty-
six-like transcription factor-1, thereby regulating the pro-
duction of TNF-α and IL-1ß.
Xuebijing is a Chinese herbal compound preparation
mainly consisting of Chuanxiong (Rhizoma Chuanxiong),
Chishao (Radix Paeoniae Rubra), Danshen (Radix Salviae
Miltiorrhiae), and Honghua (Flos Carthami). Xuebijing
can clear heat, cool blood, promote gas and blood cir-
culation, remove toxic substances, and relieve pain [16].
Furthermore, Xuebijing has been used to treat systemicinflammatory response syndrome, pyemia, and multiple
organ dysfunction syndrome [17].
In the present study, we hypothesised that Xuebijing
could reduce inflammatory-induced lung injury follo-
wing paraquat poisoning. We examined the expression
of cytokines and p38 MAPK in the lung following treat-




Xuebijing injections were obtained from Tianjin Chase
Sun Pharmaceutical Co., Ltd. (No. Z20040033; Tianjin,
China), and consisted of Chuanxiong, Chishao, Danshen
and Honghua. Chuanxiong, Chishao, Danshen and
Honghua were obtained from Prof. Li Shixia of Central
South University and deposited at the Pharmacy Centre.
Reagents
Rabbit anti-mouse NF-κB65 and p38 MAPK antibodies
were obtained from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). Mouse TNF-α, IL-1β and IL-6 ELISA
kits were purchased from Quantikine, R&D Systems
(Minneapolis, MN, USA). The Griess reagent nitric oxide
assay kit was purchased from Beyotime Biotech (Jiangsu,
China). The mouse IL-10 ELISA kit was obtained from
Bender MedSystems (Vienna, Austria). Paraquat was pur-
chased from Sigma.
Main instruments
An Olympus inverted microscope (Olympus, Tokyo,
Japan), low-temperature refrigerated centrifuge (Eppendorf,
Germany), clean bench (Suzhou Purification Equipment
Co., Ltd.), continuous wavelength microplate reader (Bio-
Rad Laboratories Inc., Hercules, CA, USA), electronic bal-
ance (Sartorius Instrument & System Engineering Co., Ltd,
Beijing, China), haemocytometer (Qiujing Biochemical In-
strument Factory, Shanghai, China), AE31 inverted phase
contrast microscope (Motic), and electric homogeniser
(Kemi Instrument & Meter Co., Ltd. Zhenjiang, China)
were used in this study.
Experimental animals
Male Sprague Dawley rats were purchased from Kunming
Medical University Laboratory Animal Center (Kunming,
China). All rats were housed at the Kunming Medical
University Animal Care Facility and were maintained in
pathogen-free conditions. Rats were 8–9 weeks of age at
the initiation of the experiment and were maintained on
standard laboratory chow and water was provided ad libi-
tum. All experiments were approved and performed ac-
cording to the guidelines of the Animal Care Committee
of Kunming Medical University.
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Danshen and Honghua
We prepared Xuebijing as previously described in the lit-
erature [18]. The appropriate amount of dried Chuanxiong,
Chishao, Danshen and Honghua was weighed and twice
backflow extractions were performed using chloroform:
methanol (2:1) at 50°C in a water bath for 2 h at each time
point. The liquid was discarded, and ultrasonic extraction
with the residue with 80% ethanol was performed three
times (20 min each) and filtered. The filtrate was discarded
for ultrasonic extraction with water three times (20 min
each) and filtered. To lower the temperature of the con-
centration of the combined filtrate, 95% ethanol was added,
and the solution was allowed to stand at a low temperature
for 24 h. To obtain Xuebijing, several washes were per-
formed and the solids were extracted and filtered with ab-
solute ethanol and acetone prior to vacuum drying.
HPLC determination of Xuebijing
Analyses were performed using a liquid chromatography
system (Waters, Milford, MA, USA) with 515 pumps,
equipped with an online degasser, a Waters pump con-
trol module, an autosampler 717, a Waters 2996 pho-
todiode array detector, and Waters Empower software.
Separation was performed using a Supelcosil LC-8-DB
column (250 × 4.6 mm i.d.; 5 μm pore size) with a guardFigure 1 Chromatogram of the chemical reference substances and sa
B: Chromatogram showing the following samples: 1, uridine; 2, gallic acid;
aldehyde; 7, ferulic acid; 8, salvianolic acid B; 9, safflor yellow A; 10, senkyuncolumn (40 × 4.6 mm i.d.) packed with the same material.
The column was maintained at 25°C throughout the ana-
lysis, and detection was performed at 254 nm. Elution was
performed at a flow rate of 0.8 mL/min with water as sol-
vent A and methanol as solvent B. In addition, an isocratic
elution from 0–10 min with 90% of A followed by a gradi-
ent elution from 10–15 min with 90–85% of A, 15–30
min with 85–70% of A, 30–37 min with 70–90% of A, and
isocratic from 37–45 min with 90% of A was performed.
A stock solution of Xuebijing (1 mg/mL) was prepared in
methanol and analysis was performed under the same
working conditions. Each analysis was repeated three
times, and the respective retention times were averaged.
Peak identification in HPLC analysis was performed by
comparing the retention time with the reference standard.
Quantification of the compounds was achieved using the
calibration plot of the standard solution.
The concentrations for the standard used for the cali-
bration curve ranged from 1.0 μg to 5.0 μg for Xuebijing.
Each run was repeated three times.
Chromatography was performed at room temperature
with a flow rate of 1.0 mL/min, and 10 μL of volume
was analysed. Analysis (Figure 1) showed that 1 L of the
Xuebijing injection contained 38.61 mg uridine, 11.98
mg gallic acid, 27.04 mg guanosine, 48.33 mg danshensu
sodium, 7.15 mg paeoniflorin, 19.6 mg protocatechuicmple. A: Chromatogram of the chemical reference substances.
3, guanosine; 4, danshensu sodium; 5, paeoniflorin; 6, protocatechuic
olide; and 11, senkyunolide.
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B, 48.66 mg safflor yellow A, 53.15 mg senkyunolide I,
and 19.29 mg senkyunolide.
Animal groupings and drug administration
Briefly, rats were randomly assigned into one of four groups:
the saline control group, paraquat group, Xuebijing + para-
quat group and dexamethasone + paraquat group (n = 20
for each group). From previous experiments and reports
[2,16], ALI was induced by an intraperitoneal paraquat
injection (30 mg/kg) and left untreated for 1 h. Sub-
sequently, rats were given either Xuebijing 8 mL/kg,
dexamethasone 5 mg/kg or 300 μl of normal saline via in-
jection into the tail vein. Three to five rats from each
group were anaesthetised and killed at 48-h post-injection
of paraquat for cytokine concentration measurements, as-
sessment of lung injury, and histology.
Collection of bronchoalveolar lavage fluid (BALF) and
tissue samples
Rats were euthanised and their thoraxes were opened
via a midline thoracotomy. Three millilitres of blood was
collected from the heart and centrifuged at 2000 × g at
4°C for 10 min. The serum was collected and stored
at −80°C until further analysis. After euthanising the
rats, the trachea was isolated and the right bronchial
tube was ligated. BALF was obtained by placing a
20-gauge catheter into the trachea through which 3 mL
of cold PBS was flushed back and forth three times.
BALF was centrifuged at 3000 × g for 20 min at 4°C. The
resulting cell pellet was used to determine the total cell
count using a counter (Beckman Coulter). A cell smear
was made using Wright–Giemsa staining to confirm the
percentage of inflammatory cells. The protein concentra-
tion of the cell-free BALF from all groups was measured
using a Bio-Rad protein assay kit and was used as an
indication of endothelial and epithelial permeability. The
right middle lung lobes were stored in liquid nitrogen at
−80°C until analysis. The right upper lobes were used to
quantify the magnitude of pulmonary oedema. The right
lower lobes were used for histological evaluation.
Western blotting
Lung tissues were homogenised in lysis buffer containing
protease inhibitors, and protein concentrations were
determined using Bradford reagent (Bio-Rad). Samples
were loaded onto an SDS-PAGE gel. After electropho-
resis at 120 V for 90 min, the separated proteins were
transferred onto polyvinylidene difluoride membranes
(GE Healthcare, Little Chalfont, United Kingdom) by the
wet transfer method (250 mA, 90 min). Nonspecific sites
were blocked with 5% non-fat dry milk in Tris-buffered
saline with Tween 20 (25 mM Tris, pH 7.5, 150 mM
NaCl, 0.1% Tween 20) for 1 h, and the blots wereincubated overnight at 4°C with anti-TGF-β1 antibody
(Sigma-Aldrich), anti-p38 MAPK antibody (Cell Sig-
naling Technology Inc.), anti-p-p38 MAPK antibody
(R&D Systems, Inc.), anti-NF-κB65 antibody (Cell Sig-
naling Technology Inc.), anti-IκB antibody (Cell Signaling
Technology Inc.), anti-p-IκB-α antibody (Cell Signaling
Technology Inc.), anti-HIF-1α antibody (Cell Signaling
Technology Inc.), and anti-Nrf2 antibody (Cell Signaling
Technology Inc.). Anti-rabbit or anti-mouse horseradish
peroxidase conjugated-IgG antibodies were used to detect
binding of the antibodies. The membranes were stripped
and reblotted using an anti-actin antibody (Sigma-Aldrich)
to normalise the loading of protein in each lane. The
binding of specific antibodies was visualised by exposing
the membranes to photographic film after treatment
with enhanced chemiluminescence system reagents (GE
Healthcare).
Determination of the activation of NF-κB65 using
immunohistochemistry
Immunostaining was performed on lung sections after
antigen retrieval using Retrievagen A (Zymed, South San
Francisco, CA, USA) at 100°C for 20 min, and endogenous
peroxidases were quenched with 3% H2O2. Sections were
blocked with 2% BSA in PBS followed by staining with pri-
mary anti-NF-κB65 at room temperature for 1 h. Sections
were washed, and after application of the secondary
antibody (R&D Systems), tissues were developed using
Vectastain ABC (Vector Labs, Burlingame, CA, USA)
and 3,3′-diaminobenzidine (Vector Labs). Using Image
Pro Plus image analysis software (Media Cybernetics,
Bethesda, MD, USA), NF-κB65-positive expression in lung
tissue was determined and expressed as positive units.
Determination of cytokines, TGF-β1 and PIIIP in serum
using ELISA
Nalgene Nunc MaxiSorp plates were coated with primary
antibodies for either IL-6, TNF-α, IL-1β, IL-10, TGF-β1 or
PIIIP (R&D Systems) for 1 h at room temperature and
washed with PBS and 0.5% Tween 20. After blocking with
casein, the samples were added to plates for 1 h at room
temperature. Following washing, biotinylated secondary
antibodies were applied for 1 h followed by streptavidin-
HRP conjugate (Jackson ImmunoResearch, West Grove,
PA, USA) diluted at 1:20,000. The reaction was developed
with 0.01% tetramethylbenzidine dissolved in dimethyl
sulfoxide and 0.5% hydrogen peroxide and measured
using endpoint spectrometry.
Determination of the total cell number and inflammatory
cells
Using a previously described method [19], bronchoalveo-
lar lavage was performed by instilling 0.9% NaCl con-
taining 0.6 mmol/L EDTA in two separate 0.5 mL
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placed on ice for immediate processing. An aliquot of
BALF was processed immediately for total and differential
cell counts. The remainder of the lavage fluid was centri-
fuged and the supernatant was removed aseptically and
stored in individual aliquots at −70°C. Total cell counts in
BALF were determined using a haemocytometer. The
number of inflammatory cells was calculated as the per-
centage of inflammatory cells multiplied by the total
number of cells in the BALF sample. All analyses were
performed in a blind fashion.
Albumin concentration of BALF
The albumin content of the bronchoalveolar lavage
supernatant was assessed using an ELISA kit for albumin
(E91028Mu; Uscn Life Science Inc., Wuhan, China).
Measurement of the absorbance at 450/540 nm was per-
formed using a microplate reader (Infinite 200; Tecan
Group, Zürich, Switzerland).
Measurement of pulmonary oedema
Total lung water content, a quantification of pulmonary
oedema, was measured as previously described [20]. The
left lung was isolated for determination of total lung
water content. The lung was weighed using an automatic
electric balance (Sartorius, Goettingen, Germany) and
was placed in an oven at 80°C for 48 h before being
weighed again to obtain its dry weight. Total lung water
content was calculated as follows: total lung water
content = (wet lung weigh − dry lung weight)/(dry lung
weight).
Measurement of intracellular ROS
ROS was measured using a previously described method
[21]. BAL cells were washed with PBS. To measure intra-
cellular ROS, cells were incubated for 10 min at room
temperature with PBS containing 3.3 μM 2′,7′-dichloro-
fluorescein (DCF) diacetate (Molecular Probes, Eugene,
OR, USA) to label intracellular ROS. We performed
fluorescence-activated cell sorting analysis with DCF
stained cells (1 × 104 cells) in BALF to measure ROS levels
using a FACSCalibur (BD Biosciences, San Jose, CA,
USA). The data were analysed using CellQuest Pro (BD
Biosciences).
Measurement of glutathione and oxidised glutathione in
lung tissues
Lung tissues were homogenised with 10 mL of ice-cold
lysis buffer (50 mM phosphate buffer containing 1 mM
EDTA) per gram of tissue. After centrifugation at
10,000 × g for 15 min at 4°C, the supernatant was re-
moved, deproteinated, and stored at −20°C until further
analyses. Total glutathione and oxidised glutathione levels
were determined using a glutathione assay kit (CaymanChemical Co., Ann Arbor, MI, USA), according to the
manufacturer’s protocol.
Determination of the total lung collagen content
The total lung collagen content was determined using the
Sircol Collagen Assay Kit (Biocolor Ltd., Belfast, Northern
Ireland) according to the manufacturer’s protocol.
Lung histopathology
Lung tissues were fixed in 4% paraformaldehyde, em-
bedded in paraffin, and cut into 5-μm thick sections.
Sections were stained with hematoxylin and eosin, and
images were taken with a Nikon Eclipse E800 micro-
scope (200 ×). For the lung injury score, images were
evaluated by an investigator who was blinded to the
identity of the slides, as previously described [6]. Briefly,
the extent of the pathological lesions was graded from 0
to 3 as shown in Table 1. The score for each animal was
calculated by dividing the total score for the number of
sections observed.
Statistical analysis
Data are expressed as mean ± SEM, unless otherwise in-
dicated. Data were analysed using ANOVA followed by
the Newman-Keuls comparison. For two-group compari-
sons, an unpaired Student’s t-test was used (GraphPad




To determine the effect of Xuebijing on histological lung
injury, histopathological analysis was performed on sec-
tions stained with haematoxylin and eosin. As show the
Figure 2, Histological analyses of lungs following paraquat
exposure revealed that the capillaries in the lung tissue ex-
panded and became congested by the significant increase
in neutrophils. Additionally, lung septa thickened and did
not show any improvement 48 h later, and lung injury
score was markedly increased. Xuebijing + paraquat group
rats also displayed moderate injury, but the severity was
significantly ameliorated and lung injury score signi-
ficantly decreased compared with the paraquat group,
and compared with the dexamethasone + paraquat group,
there were no significant differences.
Xuebijing inhibited the expression of p-p38 MAPK,
NF-κB65, p-IkB-α, HIF-1α and TGF-β1, and up-regulated
IkB and Nrf2 in paraquat-induced lung tissue
To assess the potential role of Xuebijing in paraquat-
induced ALI, we determined the levels of p-p38 MAPK,
NF-κB65, IkB, p-IκB-α, HIF-1α, Nrf2 and TGF-β1 pro-
teins in lung tissue of paraquat-induced ALI rats using
western blotting at 24 h after paraquat challenge (Figure 3).
Table 1 Acute lung injury pathology scoring criteria
Score Alveolar septa Alveolar haemorrhage Intra-alveolar fibrin Intra-alveolar infiltrations per field
0 All are thin and delicate No haemorrhage No intra-alveolar fibrin Less than 5 intra-alveolar cells
1 Congested alveolar septa in
less than 1/3 of the field
Erythrocytes per alveolus in
1 to 5 alveoli
Fibrin strands in less than 1/3
of the field
5 to 10 intra-alveolar cells
2 Congested alveolar septa in
1/3 to 2/3 of the field
At least 5 erythrocytes per alveolus
in 5 to 10 alveoli
Fibrin strands in 1/3 to 2/3 of
the field
10 to 20 intra-alveolar cells
3 Congested alveolar septa in
greater than 2/3 of the field
At least 5 erythrocytes per alveolus
in more than 10 alveoli
Fibrin strands in greater than
2/3 of the field
More than 20 intra-alveolar cells
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MAPK, NF-κB65, HIF-1α, p-IκB-α and TGF-β1 expres-
sion showed significant increases, and Nrf2 and IkB ex-
pression was significantly reduced. However, Xuebijing
significantly attenuated the expression of p-p38 MAPK,
NF-κB65, HIF-1α, p-IκB-α and TGF-β1, and up-regulated
Nrf2 and IkB expression, and compared with the dexa-
methasone + paraquat group, there were no significant
differences.
Xuebijing inhibited the activation of NF-κB65 in
paraquat-induced lung tissue
Lung activation of NF-κB65 was very weak at 48 h in the
control group (Figure 4). However, NF-κB65 expressionFigure 2 Changes in lung pathology and lung injury score. A: Represe
c: Xuebijing + paraquat group, d: dexamethasone + paraquat group). B: Sta
**P < 0.01 compared with control group; #P < 0.05 compared with paraquat
dexamethasone + paraquat group.was markedly increased in the paraquat and Xuebijing +
paraquat groups. At 48 h after Xuebijing administra-
tion, activation of NF-κB65 was markedly inhibited in the
Xuebijing + paraquat group, and compared with the dexa-
methasone + paraquat group, there were no significant
differences.
Xuebijing treatment attenuated systemic inflammation
Serum was collected at 48 h to evaluate the levels of
TNF-α, IL-1β, IL-6, and IL-10. As shown the Figure 5,
paraquat caused a significant acute systemic inflammatory
response as demonstrated by the increased serum concen-
trations of the pro-inflammatory mediators TNF-α, IL-1β,
and IL-6. The presence of Xuebijing reduced the increasentative lung pathological graphs (a: control group, b: paraquat group,
tistical analysis of lung injury score. Data are expressed as mean ± SEM.
group; P > 0.05 Xuebijing + paraquat group compared with
Figure 3 Comparison of expression levels of p-p38 MAPK, NF-κB65, p-IκB-α, IkB, HIF-1α, Nrf2 and TGF-β1 using western blotting.
A: Representative graphs of protein expression of p-p38 MAPK, NF-κB65, p-IκB-α, IkB, HIF-1α, Nrf2 and TGF-β1 (a: control group, b: paraquat group,
c: Xuebijing + paraquat group, d: dexamethasone + paraquat group). B: statistical analysis of protein expression of p-p38 MAPK, NF-κB65, p-IκB-α,
IkB, HIF-1α, Nrf2 and TGF-β1. Data are expressed as mean ± SEM. **P < 0.01 compared with control group; #P < 0.05 compared with paraquat
group; P > 0.05 Xuebijing + paraquat group compared with dexamethasone + paraquat group.
Figure 4 Effect of Xuebijing on the activation of NF-κB65 in paraquat-induced lung tissue using immunohistochemical staining (×200).
A: Representative immunohistochemical-stained graphs of NF-κB65-positive expression (a: control group, b: paraquat group, c: Xuebijing + paraquat
group, d: dexamethasone + paraquat group). B: Statistical analysis of NF-κB65-positive expression. Data are expressed as mean ± SEM. **P < 0.05
compared with control group; #P < 0.05 compared with paraquat group; P > 0.05 Xuebijing + paraquat group compared with dexamethasone +
paraquat group.
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compared with the dexamethasone + paraquat group,
there were no significant differences. Paraquat also in-
creased the serum concentration of the anti-inflammatory
cytokine IL-10. This change in IL-10 concentration was
not altered by intravenous administration of Xuebijing
and dexamethasone.
Xuebijing treatment prevented inflammatory cell
infiltration in the lungs
To investigate the potential mechanism underlying the
protective effect of Xuebijing on paraquat-induced ALI,
we detected the total number of cells, neutrophils, mac-
rophages, lymphocytes and monocytes in BALF from
rats treated with paraquat with or without Xuebijing. As
shown the Figure 6, paraquat caused a significant increase
in inflammatory cell counts in BALF at 48 h. These in-
creases were reduced in the Xuebijing + paraquat group,
and compared with the dexamethasone + paraquat group,
there were no significant differences.
Xuebijing treatment ameliorated oxidative stress
To assay the effect of Xuebijing treatment on oxidative
stress, ROS, glutathione and oxidised glutathione acti-
vities were determined. As shown in Figure 7, ROS and
oxidised glutathione activities were significantly higher,
and glutathione activity was markedly lower, at 48 h
after paraquat administration. Xuebijing treatment sig-
nificantly attenuated ROS and oxidised glutathione ac-
tivities and elevated glutathione activity, and compared
with the dexamethasone + paraquat group, there were
no significant differences.
Xuebijing treatment reduced the wet/dry weight ratio
and BALF protein concentration
The lung wet-dry weight ratio was significantly higher
at 48 h after paraquat administration. Xuebijing treat-
ment significantly attenuated this change (Figure 4A).
Additionally, with regard to endothelial and epithelialFigure 5 Xuebijing treatment suppressed the production of inflamma
were determined using ELISA. Data are expressed as mean ± SEM. **P < 0.0
with paraquat group; P > 0.05 Xuebijing + paraquat group compared with dpermeability, the BALF protein concentration quickly in-
creased after paraquat injection. The paraquat + Xuebijing
group also exhibited significantly lower protein concentra-
tions, and compared with the dexamethasone + paraquat
group, there were no significant differences (Figure 8).
Xuebijing treatment reduced TGF-β1 and PIIIP expression
Concentrations of serum TGF-β1 and PIIIP were mar-
kedly increased at 48 h after paraquat administration in
the paraquat group and Xuebijing + paraquat group;
however, the increase in TGF-β1 and PIIIP were sup-
pressed by Xuebijing in paraquat-induced rats, and com-
pared with the dexamethasone + paraquat group, there
were no significant differences (Figure 9).
Discussion
Intentional oral ingestion of even small amounts of para-
quat can cause severe and irreversible systemic damage re-
fractory to any known treatment [5]. Upon ingestion,
paraquat is rapidly distributed to most organs in the body,
but the highest concentrations are found in the kidneys
and lungs [7]. Paraquat accumulation in the lungs is facili-
tated by type I and II alveolar epithelial cells via the poly-
amine uptake pathway. Subsequent redox cycling and free
radical generation initiate a neutrophil-mediated inflam-
matory response in the lungs [10].
In the current study, paraquat was found to stimulate
the infiltration of inflammatory cells into the interstitial
and alveolar spaces, and to increase the generation of
pro-inflammatory mediators, such as IL-6, TNF-α and
IL-1β1. Pathological findings demonstrated disrupted
alveolar epithelial cells, haemorrhage, oedema, and infil-
tration of inflammatory cells into lung tissue. Treatment
with Xuebijing suppressed the infiltration of inflamma-
tory cells into the interstitial and alveolar spaces, re-
duced increases in the generation of pro-inflammatory
mediators, and extenuated lung injury.
Glucocorticoids, such as dexamethasone, are potent
anti-inflammatory drugs frequently prescribed for thetory mediators. The levels of TNF-α, IL-1β, IL-6, and IL-10 in serum
1 compared with control group; #P < 0.05 and ##P < 0.01 compared
examethasone + paraquat group.
Figure 6 Xuebijing treatment prevented inflammatory cell infiltration in paraquat-induced lung injury. Inflammatory cells in BALF were
measured. Data are expressed as mean ± SEM. **P < 0.01 compared with control group; #P < 0.05 and ##P < 0.01 compared with paraquat group;
P > 0.05 Xuebijing + paraquat group compared with dexamethasone + paraquat group.
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asthma, chronic obstructive pulmonary disease, and
acute respiratory distress syndrome [22]. In addition to
these chronic inflammatory diseases, glucocorticoids
have also been used for the treatment of severe sepsis
and septic shock in patients in the intensive care unit
[23]. Clinical trials have indicated that low dose gluco-
corticoids alleviate the systemic inflammatory response,
reduce the duration of shock, and favourably affect
survival in patients with septic shock [22]. In animal
models of endotoxic shock, prophylactic treatment withFigure 7 Effect of Xuebijing treatment on ROS, glutathione and oxidi
activities were determined. Data are expressed as mean ± SEM. **P < 0.01 c
P > 0.05 Xuebijing + paraquat group compared with dexamethasone + paradexamethasone attenuates the production of inflamma-
tory cytokines including TNF-α and IL-1β, and prevents
shock and mortality [24]. Previous studies using pro-
longed administration of corticosteroids, such as me-
thylprednisolone or dexamethasone, initiated before or
simultaneously with bleomycin reduced pulmonary in-
flammation, lung injury, and collagen deposition in this
model [25-27].
Building on this previous research, and to investigate
Xuebijing’s clinical effects, we established a dexametha-
sone group as a positive control group. We found thatsed glutathione activities. ROS, glutathione and oxidised glutathione
ompared with control group; #P < 0.05 compared with paraquat group;
quat group.
Figure 8 Effects of Xuebijing treatment on the wet/dry weight ratio and BALF protein. Data are expressed as mean ± SEM. *P < 0.05;
**P < 0.01 compared with control group; #P < 0.05 and ##P < 0.01 compared with paraquat group; P > 0.05 Xuebijing + paraquat group compared
with dexamethasone + paraquat group.
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lung p-p38 MAPK, NF-κB65, HIF-1α, p-IκB-α and TGF-
β1 expression, increasing Nrf2 expression, inhibiting the
inflammatory response and oxidative stress, and extenu-
ating paraquat-induced lung injury.
The present study investigated the effect of Xuebijing
on paraquat-induced extra-pulmonary ALI. The experi-
mental model was previously validated as a model of
ALI [28], and there is evidence that the metabolic pro-
cesses, immuno-inflammatory features and histological
lung damage in acute paraquat intoxication are similar
in humans and rats [29,30]. The dose of paraquat used
(30 mg/kg of body weight. i.p.) may be classified as mod-
erate exposure to paraquat (60% of the LD50) in rats
(LD50 = 50 mg/kg) and high exposure in humans, con-
sidering a human LD50 of 35 mg/kg [31]. This dose was
sufficient to induce an inflammatory response with in-
creased cell migration and resulted in lung injury, as
demonstrated by lung oedema, haemorrhage, alveolar ob-
struction and collapse. Results from the study showed that
Xuebijing treatment markedly inhibited the secretion ofFigure 9 Xuebijing treatment inhibited the generation of TGF-β1 and
ELISA. Data are expressed as mean ± SEM. **P < 0.01 compared with contro
P > 0.05 Xuebijing + paraquat group compared with dexamethasone + parainflammatory mediators, reduced cell migration, atte-
nuated lung oedema, haemorrhage, alveolar obstruction
and collapse.
The inflammatory reaction plays an important role in
ALI in patients following paraquat poisoning, with the
release of pro-inflammatory factors resulting in systemic
inflammatory response syndrome, as well as the release
of anti-inflammatory factors [4]. Clinically, the expres-
sion of inflammatory cytokines in the blood is signifi-
cantly elevated in patients with paraquat poisoning [14].
A limited number of transcription factors regulate the
inflammatory pathways, of which the most important
transcriptional regulator is NF-κB [32]. Following activa-
tion by a wide array of mediators, including cytokines,
bacterial toxins, or oxidative stress, the signal transduction
cascade is initiated, and activated NF-κB can translo-
cate to the nucleus and bind to the promoters of pro-
inflammatory genes, leading to enhanced gene expression
and amplification of the inflammatory response. IκB-α
(nuclear factor of kappa light polypeptide gene enhancer
in B-cells inhibitor, alpha) is one member of a family ofPIIIP. Levels of TGF-β1 and PIIIP in serum were determined using
l group; #P < 0.05 and ##P < 0.01 compared with paraquat group;
quat group.
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tion factor. IκB-α inhibits NF-κB by masking the nuclear
localisation signals of NF-κB proteins and keeping them
sequestered in an inactive state in the cytoplasm [33]. In
addition, IκB-α blocks the ability of NF-κB transcription
factor to bind to DNA, which is required for NF-κB’s
proper functioning [34]. As the expression of these pro-
inflammatory mediators is modulated by NF-κB, blocking
NF-κB transcriptional activity may be an important target
for treating inflammatory diseases.
Paraquat stimulation elicits a cascade which increases
p-IκB-α expression and reduces IkB expression, resulted
in the activation of NF-κB and the enhanced secretion
of pro-inflammatory mediators, which results in lung
injury.
The MAPK signalling pathway in macrophages is one
of the most extensively investigated intracellular sig-
nalling cascades involved in lipopolysaccharide-induced
pro-inflammatory responses [35], which are classified
into at least three components: extracellular signal-
regulated kinases 1/2, c-Jun N-terminal kinase, and p38
MAPK, and which have been implicated in the release of
immune-related cytotoxic factors and pro-inflammatory
cytokines [35]. p38 MAPK is a key mediator of cellular
stressors such as inflammation and apoptosis. Both
in vitro and in vivo studies have shown that p38 MAPK
regulates the production of pro-inflammatory cytokines
IL-6 and TNF-α by increasing cytokine release or mes-
senger RNA transcription [36]. Earlier reports revealed
that inhibitors of p38 MAPK (SB203580) reduce lipopoly-
saccharide-induced pro-inflammatory protein levels [37].
Numerous basic and clinical studies have demonstrated
that overexpression of TNF-α and IL-1ß can induce lung
injury and that cytokine production is associated with acti-
vation of the p38 MAPK pathway [35-38]. Results from
our study indicate that paraquat increased p-p38 MAPK
expression and further stimulated expression of TNF-α
and IL-1ß. However, the increase in p-p38 MAPK expres-
sion was inhibited by Xuebijing which inhibited the ex-
pression of TNF-α and IL-1ß.
Several lines of evidence suggest that MAPK can
participate in the activation of NF-κB in the cytoplasm
as well as in the modulation of its transactivation poten-
tial in the nucleus. As the expression of these pro-
inflammatory mediators is modulated by NF-κB, block-
ing NF-κB transcriptional activity may be an important
target for treating inflammatory diseases. Our findings sug-
gest that the inhibition of MAPK pathways by Xuebijing
may be a major mechanism underlying the attenuation of
paraquat-induced NF-κB transcriptional activity.
Oxidative stress is a sign of inflammation. Previous
studies on various lung inflammation diseases have con-
firmed that oxidative stress and oxidative damage are
closely related to the development and severity of ALI/acute respiratory distress syndrome [39]. An imbalance
between ROS and the antioxidant defence system results
in oxidative stress, which is closely linked to the patho-
genesis of acute and chronic lung injury [39]. Increased
levels of ROS can cause direct tissue injury and promote
inflammatory responses via the regulation of diverse
pro-inflammatory mediators in the lungs. The response
of a cell to excessive ROS involves the activation of
multiple signalling pathways, which can cause transcrip-
tional changes and, consequently, exhibit a variety of
activities [40,41]. NF-κB is one of the major transcription
factors activated in the lung during oxidative stress, lea-
ding to an up-regulation of numerous pro-inflammatory
genes, such as T-helper 2 cytokines, which can affect lung
injury [42-44]. ROS also attenuates the transcriptional
activity of nuclear factor E2-related factor 2 (Nrf2) and
stimulates hypoxia-inducible factor (HIF)-1α expression,
resulting in a greater expression of their target genes
[45-47]. Some studies have also indicated that ROS func-
tions as a signalling molecule and can stimulate HIF-1α
protein synthesis via the activation of the PI3K/AKT and
p42/p44 MAPK pathways. Furthermore, ROS may also
have the potential to interfere with prolyl hydroxylase ac-
tivity to regulate HIF-1α expression. Glutathione synthe-
sised from cysteine is a vital protective antioxidant against
oxidative stress. Our research found that paraquat down-
regulated Nrf2 expression via increasing NF-κB, HIF-1α
and MAPK activity, increased ROS activity, and inhibited
glutathione activity. Expectedly, Xuebijing treatment up-
regulated Nrf2 expression via the reduction of the increase
in NF-κB, HIF-1α and MAPK activity, markedly enhanced
glutathione activity, and improved paraquat-induced lung
injury.
TGF-β1 is known to enhance the fibrotic process by
enhancing fibroblast growth and collagen production as
well as promoting the differentiation of fibroblasts into
myofibroblasts, which secrete collagen and other extra-
cellular matrix components [48]. In addition, TGF-β1
can affect several signal transduction pathways in a
Smad-independent manner, such as MAPK, including
extracellular signal-related protein kinase, p38 MAPK,
and c-Jun N-terminal kinase [49].We also examined
TGF-β1 expression in the present paraquat-induced
mouse model. Consistent with these previous findings,
our results showed that expression of TGF-β1 and p-p38
MAPK increased after paraquat challenge, and adminis-
tration of Xuebijing in paraquat-induced rats decreased
the increased expression of TGF-β1 by blocking the p38
MAPK pathway.
PIIIP is a crucial component of type III collagen synthe-
sis and is the major collagenous factor in fibrosis [50].
Current perspectives suggest that the increased synthesis
of collagen type I, III, and V may play an important role in
the pathophysiological mechanism, resulting in intestinal
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gen, namely, an increase in procollagen type III, has been
well documented in fibrotic processes involving other or-
gans, such as the liver, pancreas and lung [52]. In this
study, we found that paraquat significantly enhanced type
III collagen synthesis. However, Xuebijing markedly re-
duced the production of PIIIP by inhibiting TGF-β1 and
p38 MAPK expression.
Vascular leakage in multiple organs is a characteristic
pathological change in paraquat-induced lung injury
[53]. In the present study, we evaluated the wet/dry ratio
of the lung and found that Xuebijing treatment atte-
nuated the development of pulmonary oedema, as deter-
mined by the significant decrease in lung wet/dry ratio.
As another index of ALI caused by paraquat adminis-
tration, we measured the total protein concentration in
BALF, which indicates epithelial permeability and pul-
monary oedema [54]. As expected, paraquat treatment
was found to cause a significant increase in BALF pro-
tein concentration. Paraquat-induced increases in totalFigure 10 Charts of the mechanisms of the effects of paraquat and X
paraquat-induced lung injury. B: Chart of the mechanisms of the effectprotein in BALF were inhibited by Xuebijing through
regulating the p38 MAPK pathway.
Xuebijing is a plant-derived Traditional Chinese Medicine
that has been successfully applied to treat inflammation-
associated diseases, such as sepsis and severe pneumonia
[16]. Some studies have revealed its specific effects on vari-
ous immunomodulatory factors and processes. Xuebijing
treatment of peripheral blood mononuclear cells stimu-
lated by exposure to purified bacterial endotoxin lipopoly-
saccharide has resulted in decreases in tissue factor and
protease-activated receptor expression [17]. Severe pneu-
monia patients treated with Xuebijing have shown de-
creased secretion of TNF-α, IL-6 and IL-8 [55], similarly
to patients with sepsis. In addition, Xuebijing treatment,
which has been clinically administered, is an intravenous
preparation consisting of 32 traditional Chinese medicines.
The principal components include Flos Carthami, Radix
Paeoniae Rubra, Rhizoma Chuanxiong, Radix Salviae mil-
tiorrhizae [56], Radix Angelica sinensis and Herba hout-
tuyniae. Intravenous Xuebijing treatment is widely useduebijing on lung injury. A: Chart of the mechanisms of
s of Xuebijing on paraquat-induced lung injury.
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treatment of systemic inflammatory response syndrome
and multiple organ dysfunction syndrome [56]. The active
ingredients of the preparation were recently determined
using mass spectrophotometry and included safflor yellow
A, ligustrazine, tanshinol, ferulaic acid, and peoniflorin.
Ferulaic acid has been previously described for its ability
to eliminate oxygen free radicals and to prevent pul-
monary fibrosis [17,18].
This study confirmed that treatment with Xuebijing re-
duced the expression of p38 MAPK and stimulated a re-
duction in NF-κB65 activity. These findings were evident
in the paraquat + Xuebijing group. In addition, reducing
the levels of IL-6, IL-1β and TNF-α attenuated the mor-
phological lesions of lung parenchyma; however, the best
results were observed in the paraquat + Xuebijing group.
In this group, lung oedema was reduced, and there was a
slight thickening of the alveolar septum, reduction in in-
flammatory cell migration and a greater area of free alveo-
lar surface compared with the paraquat groups.
Conclusions
This study demonstrated that Xuebijing treatment re-
duced paraquat-induced extra pulmonary ALI in Sprague
Dawley rats. The results indicate the effect of its inhibitory
activities on p38 MAPK and NF-κB65, the secretion of
pro-inflammatory mediators, oxidative stress response,
the attenuation of lung permeability leakage and the re-
duction of morphological damage in lung parenchyma
(Figure 10). Further pharmacological evaluations are es-
sential to elucidate the detailed mechanism of the activity
of Xuebijing, which may provide insight on its potential to
prevent and treat extrapulmonary ALI.
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